Dr. Ming Yang is the Founder, President, and CEO of Bright Biologics LLC, with more than 25 years of experience in biopharmaceutical research and development and deep expertise in antibody discovery, engineering, and oncology drug development.

Prior to founding Bright Biologics, Dr. Yang served as Group Leader of Cell Biology at Hengenix Biotech, where he established an in vitro cell-based screening platform for oncology antibody discovery and led multiple therapeutic antibody programs, including VHH and bispecific antibodies. His work in antibody engineering, affinity optimization, Fc engineering, and functional characterization contributed to the advancement of multiple candidates into IND-enabling development and clinical studies.

Earlier in his career, Dr. Yang was a Senior Scientist at Gilead Sciences, where he led an in vitro cell-based assay group supporting drug discovery and screening.

Dr. Yang received his medical degree in China, where he also practiced medicine, and subsequently earned a Doctorate in Molecular Pharmacology in Germany. He completed postdoctoral training in Molecular Immunology at the University of Illinois Chicago and in Molecular Oncology at Amgen.

Dr. Yang is named as first inventor on nine antibody-related patent applications, including eight focused on bispecific and multispecific antibodies, and has authored or co-authored more than 30 peer-reviewed publications, including 13 as first or corresponding author. His multidisciplinary background spanning clinical medicine, cell and molecular biology, pharmacology, and antibody engineering provides a strong scientific and strategic foundation for Bright Biologics’ development of next-generation antibody therapeutics.